ACI Fraud & Abuse in the Sales and Marketing of Drugs & Medical Devices
While falling short of declaring speaker programs by pharmaceutical and medical device companies as being in strict violation of the Anti-Kickback Statute (AKS), the Office of Inspector General (OIG)’s recent guidance affirms the agency’s strong reservations about such programs. This guidance outlines several “suspect characteristics” that would give rise to liability under the AKS, leading the industry to re-evaluate how it conducts speaking events seriously. On March 18, 2021, join Partner Jane Yoon from our New York office in a robust conversation that will address the special fraud alert on speaker programs.
This session will address:
- OIG’s objections to events held at restaurants and/or a significant period of time after a product is authorized
- Points of divergence from industry practices and what companies will need to change
- Considerations for resuming in-person speaker programs after the pandemic